Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

3.945 -0.015 (-0.38%)
Streaming Delayed Price Updated: 2:34 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Scott Wagner Joins GoodRx Board of Directors
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Offering Free Telehealth Appointments to Los Angeles Residents Affected by Wildfires
From GoodRx
Via Business Wire
Assessing GoodRx Holdings: Insights From 4 Financial Analysts
Via Benzinga
GoodRx Unleashes “GoodRx for Pets,” Simplifying Access and Reducing Costs for Pet Medications
From GoodRx
Via Business Wire
GoodRx Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
From GoodRx
Via Business Wire
GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer
From GoodRx Holdings, Inc.
Via Business Wire
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction. 
Via Benzinga
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024. 
Via Benzinga
GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged
From GoodRx
Via Business Wire
GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why GoodRx Holdings Stock Was Sinking This Week
The company is growing key fundamentals. However, the improvements weren't enough to impress the market. 
Via The Motley Fool
GoodRx (GDRX) Q3 2024 Earnings Call Transcript
GDRX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx Reports Third Quarter 2024 Results
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx to Participate in Upcoming Investor Conferences
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Unveils New E-commerce Platform, Launches with Opill®
From GoodRx
Via Business Wire
GoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults
From GoodRx
Via Business Wire
Ronald E. Bruehlman Joins GoodRx Board of Directors
From GoodRx
Via Business Wire
GoodRx Announces New Affordability Programs for Menopause Hormone Therapies
From GoodRx
Via Business Wire
GoodRx Partnering with Retail Pharmacies to Deliver Pay-Over-Time Option Directly to Consumers
From GoodRx
Via Business Wire
GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)
From GoodRx
Via Business Wire
GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
GoodRx to Participate in Upcoming Investor Conferences
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx (GDRX) Q2 2024 Earnings Call Transcript
GDRX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges
GoodRx reported Q2 revenue of $200.61M, a 6% YoY increase. Prescription transactions revenue rose 7%, driven by 8% growth in Monthly Active Consumers. The company expects FY 2024 revenue at the lower... 
Via Benzinga
GoodRx Reports Second Quarter 2024 Results
From GoodRx Holdings, Inc.
Via Business Wire
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
GoodRx Announces Date for Second Quarter 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS